Effect of Supplementation of a Butyrate-Based Formula in Individuals with Liver Steatosis and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial

被引:3
|
作者
Fogacci, Federica [1 ]
Giovannini, Marina [1 ]
Di Micoli, Valentina [1 ]
Grandi, Elisa [1 ]
Borghi, Claudio [1 ]
Cicero, Arrigo Francesco Giuseppe [1 ]
机构
[1] Alma Mater Studiorum Univ Bologna, Med & Surg Sci Dept, Hypertens & Cardiovasc Risk Res Unit, I-40100 Bologna, Italy
关键词
butyrate; clinical trial; dietary supplement; NAFLD; postbiotics; DISEASE; MICROBIOME; KINASE; INDEX;
D O I
10.3390/nu16152454
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Postbiotics could exert different metabolic activities in animal models of non-alcoholic fatty liver disease (NAFLD) and in humans affected by metabolic syndrome. This is a randomized, double-blind, placebo-controlled, parallel-group clinical trial that enrolled a sample of 50 Caucasian healthy individuals with NAFLD, defined as liver steatosis, and metabolic syndrome. After a 4-week run-in, the enrolled individuals were randomized to take a food for special medical purposes with functional release, one tablet a day, containing calcium butyrate (500 mg/tablet), zinc gluconate (zinc 5 mg/tablet), and vitamin D3 (500 IU/tablet), or an identical placebo for 3 months. Liver and metabolic parameters were measured at baseline and at the end of the study. No subject experienced any adverse events during the trial. In both groups, a significant decrease in total cholesterol (TC) and triglycerides (TG) plasma levels was observed at the randomization visit vs. pre-run-in visit (p < 0.05). Regarding liver parameters, after treatment, the fatty liver index (FLI) improved significantly vs. baseline values (p < 0.05) and vs. placebo group (p < 0.05) in the active treatment group, and the hepatic steatosis index (HSI) improved significantly vs. baseline values (p < 0.05). Moreover, after active treatment, TC, TG, and gamma-glutamyl transferase (gGT) improved significantly vs. baseline values (p < 0.05), and TC and TG improved vs. placebo group (p < 0.05), as well. In the placebo group, liver parameters remained unchanged after treatment; only TG improved significantly vs. baseline values (p < 0.05). In our study, we observed that the butyrate-based formula improved FLI and plasma lipid patterns in individuals affected by liver steatosis and metabolic syndrome.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Pterostilbene on Metabolic Parameters: A Randomized, Double-Blind, and Placebo-Controlled Trial
    Riche, Daniel M.
    Riche, Krista D.
    Blackshear, Chad T.
    McEwen, Corey L.
    Sherman, Justin J.
    Wofford, Marion R.
    Griswold, Michael E.
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 2014
  • [22] The effect of synbiotic supplementation on hypothyroidism: A randomized double-blind placebo controlled clinical trial
    Ramezani, Majid
    Reisian, Mahnaz
    Hezaveh, Zohreh Sajadi
    PLOS ONE, 2023, 18 (02):
  • [23] Effect of prebiotic and probiotic supplementation on reduced pain in patients with fibromyalgia syndrome: a double-blind, placebo-controlled randomized clinical trial
    CIn, Nazli Nur Aslan
    Acik, Murat
    TertemIz, Oktay Faysal
    Aktan, Cile
    Akcali, Didem Tuba
    Cakiroglu, Funda Pinar
    OzcelIk, Ayse Ozfer
    PSYCHOLOGY HEALTH & MEDICINE, 2024, 29 (03) : 528 - 541
  • [24] The effect of cumin supplementation on metabolic profiles in patients with metabolic syndrome: A randomized, triple blind, placebo-controlled clinical trial
    Morovati, Ashti
    Gargari, Bahram Pourghassem
    Sarbakhsh, Parvin
    Azari, Hushyar
    Lotfi-Dizaji, Lida
    PHYTOTHERAPY RESEARCH, 2019, 33 (04) : 1182 - 1190
  • [25] Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial
    Raqib, Rubhana
    Sarker, Protim
    Mily, Akhirunnesa
    Alam, Nur Haque
    Arifuzzaman, Abu Saleh Mohammed
    Rekha, Rokeya Sultana
    Andersson, Jan
    Gudmundsson, Gudmundur H.
    Cravioto, Alejandro
    Agerberth, Birgitta
    BMC INFECTIOUS DISEASES, 2012, 12
  • [26] Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial
    Rubhana Raqib
    Protim Sarker
    Akhirunnesa Mily
    Nur Haque Alam
    Abu Saleh Mohammed Arifuzzaman
    Rokeya Sultana Rekha
    Jan Andersson
    Gudmundur H Gudmundsson
    Alejandro Cravioto
    Birgitta Agerberth
    BMC Infectious Diseases, 12
  • [27] Effect of Diamel in patients with metabolic syndrome: A randomized double-blind placebo-controlled study
    Cabrera-Rode, Eduardo
    Orlandi, Neraldo
    Padron, Yaneysi
    Arranz, Celeste
    Olano, Raysa
    Machado, Mayra
    Hernandez-Yero, Arturo
    Calderin, Raul
    Dominguez, Emma
    JOURNAL OF DIABETES, 2013, 5 (02) : 180 - 191
  • [28] Effects of creatine supplementation on renal function: a randomized, double-blind, placebo-controlled clinical trial
    Gualano, Bruno
    Ugrinowitsch, Carlos
    Novaes, Rafael Batista
    Artioli, Guilherme Gianini
    Shimizu, Maria Heloisa
    Seguro, Antonio Carlos
    Harris, Roger Charles
    Lancha, Antonio Herbert, Jr.
    EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY, 2008, 103 (01) : 33 - 40
  • [29] Tolerability of glutamine supplementation in older adults: a double-blind placebo-controlled randomized clinical trial
    de Nobrega, T. C. M.
    da Silva, M. A. R. C. P.
    Rampani, E. M.
    Curi, R.
    Bazotte, R. B.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2024, 57
  • [30] Effects of creatine supplementation on renal function: a randomized, double-blind, placebo-controlled clinical trial
    Bruno Gualano
    Carlos Ugrinowitsch
    Rafael Batista Novaes
    Guilherme Gianini Artioli
    Maria Heloisa Shimizu
    Antonio Carlos Seguro
    Roger Charles Harris
    Antonio Herbert Lancha
    European Journal of Applied Physiology, 2008, 103 : 33 - 40